Rapport Therapeutics, Inc./$RAPP
1D1W1MYTD1Y5YMAX
About Rapport Therapeutics, Inc.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
- Ticker
- $RAPP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 84
- Headquarters
- Boston, United States
- Website
- www.rapportrx.com
RAPP Metrics
BasicAdvanced
$2.5B
-
-$3.05
0.97
-
Price and volume
Market cap
$2.5B
Beta
0.97
52-week high
$51.38
52-week low
$14.11
Average daily volume
289K
Financial strength
Current ratio
15.721
Quick ratio
15.352
Long term debt to equity
1.805
Total debt to equity
2.389
Profitability
EBITDA (TTM)
-152.556
Gross margin (TTM)
-109.39%
Net profit margin (TTM)
-685.80%
Operating margin (TTM)
-767.58%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
-25.78%
Return on equity (TTM)
-39.96%
Valuation
Price to revenue (TTM)
114.964
Price to book
5.8
Price to tangible book (TTM)
5.8
Price to free cash flow (TTM)
-23.668
Free cash flow yield (TTM)
-4.23%
Free cash flow per share (TTM)
-2.162
Growth
Earnings per share change (TTM)
21.80%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.